Azienda Ospedaliera Universitaria Integrata Verona
aovr.veneto.itTotal trials
94
Active
19
Phase 3
9
Total enrollment
42,105
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| FOLFOX and PIPAC | — | — | — | — | — | 1 | |
| Tamoxifen Citrate 20Mg Tab | — | — | — | — | — | 1 |
Next readouts
- 2025-09-30
- 2026-04-01
Top conditions
- Postoperative Complications5
- Pancreatic Fistula4
- Pancreatic Cancer4
- Surgical Site Infection3
- COVID-193
- Obesity3
- Gastric Cancer2
- Cataract2
Frequently asked questions about Azienda Ospedaliera Universitaria Integrata Verona
- How many clinical trials does Azienda Ospedaliera Universitaria Integrata Verona have on ClinicalTrials.gov?
- Azienda Ospedaliera Universitaria Integrata Verona is listed as the lead sponsor on 94 clinical trials in ClinicalTrials.gov, 19 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Azienda Ospedaliera Universitaria Integrata Verona's trials are in Phase 3?
- 9 of Azienda Ospedaliera Universitaria Integrata Verona's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Azienda Ospedaliera Universitaria Integrata Verona focus on?
- Azienda Ospedaliera Universitaria Integrata Verona's most-studied conditions on ClinicalTrials.gov are Postoperative Complications, Pancreatic Fistula, Pancreatic Cancer, Surgical Site Infection, COVID-19.
- When are Azienda Ospedaliera Universitaria Integrata Verona's next clinical trial readouts?
- Azienda Ospedaliera Universitaria Integrata Verona has 2 upcoming primary-completion readouts tracked here; the soonest is “PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer”, expected around 2025-09-30.